

BTB Japan

Company Overview

as of June 2017

- I. Facts of the Company**
- II. Executive Officers & Advisors**
- III. Business Objective**
- IV. Existing Business**
- V. Contact Information**

I. Facts of the Company

1. Name **BTB Japan, Inc.**
 2. Location **4F Le Gratte-Ciel Bldg. 3, 5-22-3 Shinbashi, Minato-ku, Tokyo 105-0004, Japan**
 3. Contact Person **CEO, Isao Kikuchi**
 4. Establishment **Sept 3, 2012**
 5. Employees & Retained Advisors; **7**
 6. Pre-History;
 - May 2005** **Masa Japan as the agent for USA Life Science Fund named MLSV (Masa Life Science Ventures) has started coordination job to invite and to be joined by Japanese investors as limited partners. 5 Japanese investors have participated.**
 - March 2009** **The activity of Masa Japan has been transferred to Acube Inc.**
 - Oct. 2009** **Started to work as sole importer of USA [Maxcyte](#) Cell Transfection System (STX)**
 - Oct. 2010** **As the agent for USA Life Science Fund named [Epidarex](#) started coordination job to invite and to be joined by Japanese investors as limited partners. 3 Japanese investors have participated.**
 - August 2011** **Started to work as an agent for Germany [Cevac Pharmaceutical](#) to introduce Human Amniotic Cell (CAP & CAP-T)**
 - Sept 2012** **Bio-Technology Business is transferred from Acube Inc. to newly established company named [BTB Japan Inc.](#)**
-

II.a Executive Officers & Advisors in Japan

Name	Title/Current/Former Affiliation and Expertise
Kikuchi, I.	CEO: Former general manager of Marubeni Corporation (one of major Japanese trading companies) then worked for Masa Inc. and Acube Inc. (biotech consulting firms) .
Yamada, Y.	Advisor, PhD(Pharmacology): Former head of a laboratory at Taiho Pharma (a Otsuka Pharma group)
Ito, K	Advisor, PhD(Pharmacology): Former bio-tech analyst in Nikko Antfactory K.K, a VC and now working as CEO at a JPN bio venture company
Nakayoshi, H.	Advisor, PhD(virology): Former director of Nomura BioScience Institute, the first person who introduced a clinical CRO to JPN.
Mori, T.	Advisor, PhD(Pharmacology): Former head of a laboratory at Ono Pharma
Itaya, H.	Advisor, Former Affymetrix Japan Representative and Former general manager at Hitachi Chemical Industries, Japan

II.b Representative and Advisors in USA and China

Name	Title/Current/Former Affiliation and Expertise
Michael Hertzberg	Representative in USA; President, Global Trade Strategies International, LLC (medical device international business development company) and Vice President, Finnish Technology Development, LLC, International Trade Law and Entrepreneurial International Business Development background
Eugene Bauer	Advisor, MD; Founder and Chief Medical Officer at Dermira, Inc. (Dermatology) Former Professor(Emeritus) in the school of Medicine at Stanford Univ.
Chuck Hewitt	Advisor, PhD: CEO and Co-Founder of ImmunO4 LLC. (Chemiluminescent Substrate) , Managing Partner of Epic BioVentures, LLC., Former CEO of BioFX Laboratories Inc.
Kirby S. Black	Advisor, PhD(Immunology/Cell Biology), Managing Partner, Epic BioVentures, LLC. Former Professor of Biotechnology, Kennesaw State Univ.
Yongping Yu	Representative in China; PhD(Chemistry), Professor and Director Academic Committee at College of Pharmaceutical Sciences, Zhejiang, China

III. Business Objective

As an intermediate agent, BTB Japan has been focusing on innovative products/technologies in the life-science field.

- 1. To US and EU bio-ventures;** cost effective inroad into the JPN market.
- 2. To JPN pharmaceutical companies;** providing information and assistance regarding innovative technologies and also drug candidates or seeds.
- 3. To JPN bio-ventures;** providing information and assistance on innovative technologies as well as on possible licensing-out /collaboration opportunities with overseas.
- 4. To JPN academia;** providing information and assistance on innovative technologies and also drug candidates or seeds for their drug discovering and clinical development.
- 5. To JPN distributor for medical system/equipment/device;** providing information and assistance on innovative technologies as well as on possible licensing /collaboration opportunities with overseas.

IV. Existing Business(1)

- **Technology brokerage business(1), - the protein production-related technologies.**

We have established a relationship with JPN TOP20 pharmaceutical companies and Ab bio-ventures through the existing business and are extending to academia.

<u>Bio-Ventures</u>	<u>Proprietary technologies</u>	<u>URL</u>
MaxCyte, Inc., MD, USA	Scalable transfection apparatus (STX®) up to 10 ¹⁰ cells and reagents	www.maxcyte.com
CEVEC Pharmaceuticals GmbH, Köln, Germany	Human amniocyte-derived cell line (CAP®) for protein and viral production	www.cevec.com
Selexis SA, Geneva, Switzerland	SUREtechnology® platform for development of cell-lines with stable and high-efficient expression	www.selexis.com

➤ **Technology brokerage business(2), - Seeds for unique therapeutics & diagnostics**

<p>Torrey Pines Institute for Molecular Studies (TPIMS), San Diego, CA and Port St. Lucie, FL</p>	<p>The compound library collection of over 30 million drug-like compounds and billions of peptides, arranged in the positional scanning format which allows for the testing of millions of compounds using only hundreds of samples.</p>	<p>www.tpims.org/</p>
<p>NuvOx Pharma, Tucson, Arizona</p>	<p>Innovative platform of DDFP (dodecafluoropentane)-based oxygen therapeutics to treat a host of human conditions.</p>	<p>www.nuvoxpharma.com/</p>
<p>SAJE Pharma, Baltimore, MD</p>	<p>Small molecule drugs regulate nitrosylation by inhibiting GSNOR (S-nitrosoglutathione reductase) and the resultant increase of GSNO(a storage form of NO) which increases nitrosylation of accessible cysteines on key signaling proteins.</p>	<p>www.sajepharma.com/</p>
<p>Collectar Biosciences, Madison, WI</p>	<p>The product candidates are built on a novel, cancer and cancer stem cell-targeting delivery and retention platform of optimized phospholipid ether analogs (PLEs).</p>	<p>collectarbiosciences.com/</p>

➤ **Technology brokerage business(2), continued- Seeds for unique therapeutics & diagnostics**

ImmunO4, Westminster, MD	Innovative and Efficient Chemiluminescent Substrate	www.immuno4.com
Motif Bio, UK & New York, USA	Iclaprim, Phase III antibiotic against infections caused by multi-drug-resistant bacteria	www.motifbio.com/
Nolla Antimicrobial Ltd., Helsinki, Finland	Silver Polymer chain 0.5 nanometers thickness having 10 times more antimicrobial than the any other form of silver; Usage is broad. Drug; Herpes, Eczame, Others; Sanitizer, Paper Coating, Textile Coating, Laundry, Foot Deodorizer, Cosmetics (Deodorant, Hygiene and Shaving),Mycoplasma,	www.nollaantimicrobial.com/
The Sage Group, Clinton, NJ, USA	Collaborative consulting with USA based business and investment consulting firm for its client and Japan such as; arGentis; Mid stage Orphan Drug treatment (ARG201 and ROT1) for dcSSc (Diffuse Late Stage Systemic Scleroderma) and IZUN; Curasite Wound Care Treatment (Anti-Inflammatory & Tissue Repair)	www.thesagegroup.com/
Assuage Pharmaceuticals	Developing drug with superior safety and efficacy than existing smoking cessation products; future products for other addictions.	www.assuagepharma.com/

IV. Existing Business (2)

➤ Service business

Epidarex Capital(www.epidarex.com) ; Started in October 2010. To introduce to the investors Bio-Technology developed mainly in USA and Europe is the major purpose. Such introduction is very specific to fund investors and are focused on their interests. The objective is to develop large distribution opportunities utilizing the investors' global networks. Support for Licensing and Distribution Agreement is also provided.

V. Contact Information

For more information please contact:

Isao Kikuchi

BTB Japan, Inc.

4F Le Gratte-Ciel Bldg.3, 5-22-3 Shinbashi,

Minato-ku, Tokyo 105-0004, Japan

kikuchi@btbjapan.com

Tel/Fax: +81-3-6459-0258

<http://www.btbjapan.com>